Abstract
Tolperisone HCl is a central muscle relaxant, which was incorporated in a matrix system formulated with poly(ethylene oxide)–PEO, in order to achieve adequate gastric residence time. This tablet presents considerable analytical difficulties in the quantitative determination of the drug, because the PEO matrix causes significant increase of viscosity in the samples. Our purpose was to develop a reproducible sample preparation method, which is adapted from parameters of the in vitro dissolution test and validate an LC-UV analytical method, which allows good recovery of the drug (99.97%). The developed analytical method was suitable for quantitative analysis of tolperisone HCl in matrix tablets.
This is a preview of subscription content, log in via an institution to check access.
References
Porszasz J, Barankay T, Nador K, Gibiszer K (1961) Arzneim-Forsch Drug Res 11:257–260
Fels G (1996) Arch Pharm 329:171–178
Kocsis P, Farkas S, Fodor L, Bielik N, Than M, Kolok S, Gere A, Csejtei M, Tarnawa I (2005) J Pharmacol Exp Ther 315:1237–1246. doi:10.1124/jpet.105.089805
Hofer D, Lohberger B, Steinecker B, Schmidt K, Quasthoff S, Schreibmayer W (2006) Eur J Pharmacol 538:5–14. doi:10.1016/j.ejphar.2006.03.034
Ribi C, Vermeulen C, Hauser C (2003) Swiss Med Wkly 133:369–371
Farkas S, Berzsenyi P, Kárpáti E, Kocsis P, Tarnawa I (2005) J Pharmacol Toxicol Methods 52:264–273. doi:10.1016/j.vascn.2004.11.005
Orgován G, Tihanyi K, Noszál B (2009) J Pharm Biomed Anal 50:718–723. doi:10.1016/j.jpba.2009.05.036
Sae-Lee N, Sae-Lee N (2005) SWU J Pharm Sci 10:121–124
Sae-Lee N, Sae-Lee N (2006) Thai Pharm Health Sci J 11:1–4
Liawruangrath S, Liawruangrath B (1999) J Pharm Biomed Anal 20:401-404. doi:10.1016/S0731-7085(99)00023-0
Liawruangrath S, Liawruangrath B, Pibool P (2001) J Pharm Biomed Anal 26:865–872. doi:10.1016/S0731-7085(01)00462-9
Youngvises N, Liawruangrath B, Liawruangrath S (2003) J Pharm Biomed Anal 31:629–638. doi:10.1016/S0731-7085(02)00693-3
Bae JW, Park YS, Sohn UD, Myung CS, Ryu BK, Jang CG, Lee SY (2006) Arch Pharm Res 29:339–342
Antal I, Kiss D, Orgován G, Stiedl B, Zelkó R, Klebovich I, Noszál B, European Patent Application No. PCT/HU2008/000086, Pub. No.: WO/2009/013552
Li H, Hardy RJ, Gu X (2008) AAPS PharmSciTech 9:437–443. doi:10.1208/s12249-008-9060-x
Ravichandran M, Bhaskara J, Barudaraj R, Dimitrios S, Killion R, Afredson T, Pratap A, Xiaoling L (2009) AAPS PharmSciTech 10:98–103. doi:10.1208/s12249-008-9182-1
Mueller C, Topolkaraev V, Soerens D, Hiltner A, Baer E (2000) J Appl Polym Sci 78:816–828
Schmitt RL (2003) Polyethylene oxide. In: Raymond CR, Paul JS, Paul JW (eds) Handbook of pharmaceutical excipients, 4th edn. Pharmaceutical Press and American Pharmaceutical Association, London, pp 460–461
Kiss D, Süvegh K, Zelkó R (2008) Carbohydr Polym 74:930–933. doi:10.1016/j.carbpol.2008.05.019
Thumma S, Majumdar S, ElSohly MA, Gul W, Repka MA (2008) Int J Pharm 362:126-132. doi:10.1016/j.ijpharm.2008.06.025
Zhang Z, Peng B, Yang X, Wang C, Sun G, Pan W (2009) J Pharm Pharm Sci 12:129–137
International Conference on Harmonisation (ICH) of Technical Requirements for the Registration of Pharmaceutical for Human Use (2005) Validation of analytical procedures: text and methodology Q2 (R1)
Acknowledgments
The authors wish to thank Katalin Ganzler for the advices and the Gedeon Richter Plc. for providing tolperisone HCl.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stiedl, B., Kovács-Kiss, D., Ludányi, K. et al. LC-UV Assay of Tolperisone HCl from Sustained Release Matrix Tablets. Chroma 71 (Suppl 1), 109–113 (2010). https://doi.org/10.1365/s10337-010-1525-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1365/s10337-010-1525-x